Floatz logo

Trastuzumab Deruxtecan

Soft Tissue Sarcoma (STS)

GI Innovation, Inc.antibody_drug_conjugatePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

103 Active assets in the Soft Tissue Sarcoma (STS) cohort.

Asset / SponsorPhaseRating
Palbociclib
Brown University
Phase 2BB
FILGRASTIM
University of California, Irvine
Phase 3BB
Inno-206
GI Innovation, Inc.
Phase 3BB
Eloxatin
OHSU Knight Cancer Institute
Phase 2BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB

View all 50 →

Same molecule, other indications

Trastuzumab Deruxtecan is also rated in:

HER2-low Expressing Breast CancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →